Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.47 |
| ▸ | CASP1 | P29466 | 16/20 | 0.45 |
| ▸ | CASP7 | P55210 | 12/20 | 0.45 |
| ▸ | CASP6 | P55212 | 11/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 11/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289747 | 0.83 | CASP3 (0.47) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL14288658 | 0.81 | CASP3 (0.45) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL14288652 | 0.70 | KLK5 (0.39) | — | |
| SCHEMBL14288669 | 0.70 | KLK5 (0.39) | — | |
| SCHEMBL14288625 | 0.66 | CASP3 (0.46) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL13475082 | 0.66 | CASP3 (0.46) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL14598496 | 0.65 | CASP3 (0.52) | CASP3CASP1CASP7CASP6CASP8 | |
| SCHEMBL27651948 | 0.64 | LMNA (0.38) | — | |
| SCHEMBL27410836 | 0.64 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL8289985 | 0.63 | CTSS (0.45) | CASP3CASP1CASP7CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| WO-2005039496-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CASP3 435/4885CASP1 423/4885CASP7 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.